NLRP3 and atherosclerosis: Jiang et al. [43], in their review, discussed in detail the NLRP3 inflammasome components and their pathophysiological implications in atherosclerosis, with a focus only on direct and indirect NLRP3 inflammasome inhibitors and setting aside natural components which could prove an inexpensive source of treatment in the future.